A Multicenter, Single Arm, Non-Interventional, Observational Study of Obinutuzumab to Evaluate Efficacy, Safety and Cost of Disease Management in Patients With Chronic Lymphocytic Leukemia and Comorbidities in Greece
Phase of Trial: Phase IV
Latest Information Update: 03 Aug 2018
At a glance
- Drugs Obinutuzumab (Primary) ; Chlorambucil
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Roche
- 12 Sep 2017 Planned End Date changed from 31 Oct 2019 to 30 Apr 2020.
- 12 Sep 2017 Planned primary completion date changed from 31 Oct 2019 to 30 Apr 2020.
- 17 Mar 2017 Status changed from not yet recruiting to recruiting.